Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?
Int J Infect Dis
; 102: 389-391, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: covidwho-954717
ABSTRACT
The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Síndrome de QT Prolongado
/
Gripe Humana
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
/
Hidroxicloroquina
Tipo de estudio:
Estudio de cohorte
/
Estudio pronóstico
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Revista:
Int J Infect Dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.ijid.2020.10.080
Similares
MEDLINE
...
LILACS
LIS